What’s Valeant Pharmaceuticals Intl Inc Upside After Today’s Huge Increase?

 What's Valeant Pharmaceuticals Intl Inc Upside After Today's Huge Increase?

The stock of Valeant Pharmaceuticals Intl Inc (TSE:VRX) is a huge mover today! About 111,071 shares traded hands. Valeant Pharmaceuticals Intl Inc (TSE:VRX) has declined 42.16% since April 18, 2016 and is downtrending. It has underperformed by 46.72% the S&P500.
The move comes after 8 months positive chart setup for the $8.49 billion company. It was reported on Nov, 22 by Barchart.com. We have $25.82 PT which if reached, will make TSE:VRX worth $424.50 million more.

Valeant Pharmaceuticals Intl Inc (TSE:VRX) Ratings Coverage

Out of 3 analysts covering Valeant Pharmaceuticals International (TSE:VRX), 1 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 33% are positive. $74 is the highest target while $17 is the lowest. The $31.33 average target is 27.41% above today’s ($24.59) stock price. Valeant Pharmaceuticals International has been the topic of 17 analyst reports since October 20, 2015 according to StockzIntelligence Inc. The firm has “Sector Perform” rating by RBC Capital Markets given on Monday, June 20. On Wednesday, September 7 the stock rating was maintained by RBC Capital Markets with “Sector Perform”. RBC Capital Markets maintained the shares of VRX in a report on Tuesday, January 26 with “Outperform” rating. The rating was maintained by RBC Capital Markets on Tuesday, September 20 with “Sector Perform”. TD Securities maintained Valeant Pharmaceuticals Intl Inc (TSE:VRX) on Thursday, August 11 with “Buy” rating. On Wednesday, July 20 the stock rating was maintained by TD Securities with “Hold”. The company was maintained on Friday, June 3 by RBC Capital Markets. The company was maintained on Monday, June 27 by RBC Capital Markets. The firm has “Sector Perform” rating given on Monday, October 31 by RBC Capital Markets. The stock of Valeant Pharmaceuticals Intl Inc (TSE:VRX) earned “Outperform” rating by RBC Capital Markets on Tuesday, October 20.

More notable recent Valeant Pharmaceuticals Intl Inc (TSE:VRX) news were published by: Fool.com which released: “Why Valeant Pharmaceuticals Intl Inc Stock Is Slumping Today” on November 08, 2016, also Profitconfidential.com with their article: “Valeant Pharmaceuticals Intl Inc: VRX Stock Rises Again” published on November 10, 2016, Investorplace.com published: “Valeant Pharmaceuticals Intl Inc (VRX) Stock Owners Should Ask Tougher Questions” on November 15, 2016. More interesting news about Valeant Pharmaceuticals Intl Inc (TSE:VRX) were released by: Fool.com and their article: “3 Figures in Focus When Valeant Pharmaceuticals Intl. Inc. Reports Its Q3 Results” published on November 01, 2016 as well as Profitconfidential.com‘s news article titled: “Valeant Pharmaceuticals Intl Inc: Did VRX Stock Just Bottom?” with publication date: November 03, 2016.

Valeant Pharmaceuticals International, Inc. is a pharmaceutical and medical device company. The company has a market cap of $8.49 billion. The Firm is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices). It currently has negative earnings. It operates through two divisions: Developed markets and Emerging markets.

VRX.TO Company Profile

Valeant Pharmaceuticals International, Inc., incorporated on August 9, 2013, is a specialty pharmaceutical and medical device company. The Firm is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices), which are marketed directly or indirectly in over 100 countries. The Firm operates through two divisions: Developed markets and Emerging markets. In the Developed Markets segment, it focuses on the areas of dermatology, neurology, gastrointestinal (GI) disorders, and eye health therapeutic classes. In the Emerging Markets segment, it focuses primarily on branded generics, OTC products and medical devices.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment